These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 16236860)

  • 61. Pharmacodynamics and pharmacokinetics of levofloxacin.
    Nightingale CH; Grant EM; Quintiliani R
    Chemotherapy; 2000; 46 Suppl 1():6-14. PubMed ID: 10810208
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Interaction between levofloxacin and vancomycin in rats--study of serum and organ levels.
    Mori H; Nakajima T; Nakayama A; Yamori M; Izushi F; Gomita Y
    Chemotherapy; 1998; 44(3):181-9. PubMed ID: 9612608
    [TBL] [Abstract][Full Text] [Related]  

  • 63. [Efficacy of levofloxacin in the treatment of acute exacerbation of chronic bronchitis in patients with risk factors].
    Zuck P; Veyssier P; Brumpt I
    Rev Pneumol Clin; 2004 Nov; 60(5 Pt 1):269-77. PubMed ID: 15687910
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Do intensive care patients need an individualized dosing regimen for levofloxacin?
    Tayab ZR; Hochhaus G; Kaufmann S; Jäger D; Barth J
    Int J Clin Pharmacol Ther; 2006 Jun; 44(6):262-9. PubMed ID: 16800098
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Pharmacokinetics and safety of MP-376 (levofloxacin inhalation solution) in cystic fibrosis subjects.
    Geller DE; Flume PA; Griffith DC; Morgan E; White D; Loutit JS; Dudley MN
    Antimicrob Agents Chemother; 2011 Jun; 55(6):2636-40. PubMed ID: 21444699
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Acute exacerbation of chronic bronchitis: expanding short-course therapy.
    Martinez FJ
    Int J Antimicrob Agents; 2005 Dec; 26 Suppl 3():S156-63. PubMed ID: 16543077
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Pharmacokinetics of intravenous levofloxacin administered at 750 milligrams in obese adults.
    Cook AM; Martin C; Adams VR; Morehead RS
    Antimicrob Agents Chemother; 2011 Jul; 55(7):3240-3. PubMed ID: 21576432
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Tissue and serum concentrations of levofloxacin in orthopaedic patients.
    von Baum H; Böttcher S; Abel R; Gerner HJ; Sonntag HG
    Int J Antimicrob Agents; 2001 Oct; 18(4):335-40. PubMed ID: 11691565
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Population pharmacokinetics of levofloxacin in Korean patients.
    Kiem S; Ryu SM; Lee YM; Schentag JJ; Kim YW; Kim HK; Jang HJ; Joo YD; Jin K; Shin JG; Ghim JL
    J Chemother; 2016 Aug; 28(4):308-13. PubMed ID: 25976699
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Serum and sputum concentrations of enoxacin after single oral dosing in a clinical and bacteriological study.
    Davies BI; Maesen FP; Teengs JP
    J Antimicrob Chemother; 1984 Sep; 14 Suppl C():83-9. PubMed ID: 6594325
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Optimal treatment strategies for acute exacerbations of chronic bronchitis: high-risk patients.
    Norrby SR
    Chemotherapy; 2001; 47 Suppl 4():47-52; discussion 53-4. PubMed ID: 11586005
    [TBL] [Abstract][Full Text] [Related]  

  • 72. A comparative study on the efficacy of levofloxacin and ceftazidime in acute exacerbation of bronchiectasis.
    Tsang KW; Chan WM; Ho PL; Chan K; Lam WK; Ip MS
    Eur Respir J; 1999 Nov; 14(5):1206-9. PubMed ID: 10596714
    [TBL] [Abstract][Full Text] [Related]  

  • 73. [Software modeling for better understanding of pharmacokinetic-pharmacodynamic relationships: application to azithromycin in the treatment of streptococcal tonsillitis and in acute exacerbation fo chronic bronchitis]].
    le Normand Y; Drugeon H; Abbas S; Palestro B
    Therapie; 2004; 59(1):155-62. PubMed ID: 15199685
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Penetration of ofloxacin from blood to sputum.
    Davies BI; Maesen FP; Geraedts WH; Baur C
    Drugs; 1987; 34 Suppl 1():26-32. PubMed ID: 3481324
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Pharmacometrics-based dose selection of levofloxacin as a treatment for postexposure inhalational anthrax in children.
    Li F; Nandy P; Chien S; Noel GJ; Tornoe CW
    Antimicrob Agents Chemother; 2010 Jan; 54(1):375-9. PubMed ID: 19858256
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Pharmacokinetics and pharmacodynamics of levofloxacin in intensive care patients.
    Sánchez Navarro A; Colino Gandarillas CI; Alvarez Lerma F; Menacho YA; Domínguez-Gil A
    Clin Pharmacokinet; 2005; 44(6):627-35. PubMed ID: 15910010
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Pharmacokinetics of levofloxacin in comparison to the racemic mixture of ofloxacin in man.
    Verho M; Malerczyk V; Damm D; Lehr KH
    Drug Metabol Drug Interact; 1996; 13(1):57-67. PubMed ID: 8902431
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Population pharmacokinetics of levofloxacin as prophylaxis for febrile neutropenia.
    Nomura K; Fujimoto Y; Morimoto Y; Kanbayashi Y; Matsumoto Y; Taniwaki M
    Intern Med; 2008; 47(5):375-8. PubMed ID: 18310966
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Tamsulosin alters levofloxacin pharmacokinetics in prostates derived from rats with acute bacterial prostatitis.
    Qin GD; Xiao MZ; Zhou YD; Yang J; He HX; He Y; Zeng Y
    Asian J Androl; 2013 Mar; 15(2):254-60. PubMed ID: 23353720
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Bronchial penetration of ofloxacin after single and multiple oral dosage.
    Davey PG; Precious E; Winter J
    J Antimicrob Chemother; 1991 Mar; 27(3):335-41. PubMed ID: 2037539
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.